An overview of the published research on CJC-1295, its regulatory status in Australia, and the important limitations of the existing evidence base.
Important: This page is general educational information only and does not constitute medical advice. CJC-1295 is identified by the TGA as an unapproved peptide product that has not been evaluated for safety, quality or effectiveness in Australia. This page does not promote or encourage the use of CJC-1295. Always consult a qualified, AHPRA-registered medical practitioner before making any decisions about your health.
CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH) that has attracted research interest for its interaction with growth hormone signalling pathways. This article summarises what the published literature has examined, the TGA's current position, and the important evidence limitations that are frequently absent from online discussion of this compound.
CJC-1295 is a synthetic peptide modelled on growth hormone releasing hormone, a naturally occurring hormone produced by the hypothalamus that signals the pituitary gland to release growth hormone. Natural GHRH is rapidly degraded in the bloodstream. CJC-1295 was developed with chemical modifications designed to extend its half-life, allowing more persistent interaction with GHRH receptors.
A commonly studied variant is CJC-1295 with DAC (drug affinity complex), a modification that further extends the compound's half-life. It is not an approved therapeutic good in Australia and has not been evaluated by the TGA for safety, quality or effectiveness.
TGA position: The TGA has specifically identified CJC-1295 among its list of unapproved peptide products. Unapproved therapeutic goods have not been assessed by the TGA for safety, quality or effectiveness. The TGA has issued guidance warning the public about risks associated with unapproved peptide products. Current guidance is available at www.tga.gov.au.
Published studies have examined CJC-1295's interaction with growth hormone and IGF-1 signalling pathways. Research has explored its effects on growth hormone pulse amplitude and frequency, and downstream effects on IGF-1 levels. Growth hormone levels are known to decline with age, and research into GHRH analogues has explored whether this decline can be modulated.
Some studies have also examined CJC-1295 in combination with Ipamorelin, a separate compound that acts on the ghrelin receptor. The rationale explored in this research is that the two compounds act through different receptor pathways both involved in growth hormone release.
Animal research vs. human clinical evidence: As with most compounds in this category, the published CJC-1295 evidence base includes a mix of animal model research and limited human studies. Animal model findings do not reliably predict outcomes in humans, and results observed in rodent studies cannot be assumed to translate directly to human use. The human clinical trial evidence for CJC-1295 is more limited than online discussion of this compound often suggests.
Several important limitations apply to the CJC-1295 evidence base:
CJC-1295 is not an approved therapeutic good in Australia. The TGA has specifically identified it among unapproved peptide products about which the public should exercise caution.
CJC-1295 is also on the WADA prohibited list as a growth hormone releasing hormone analogue. Competitive athletes subject to anti-doping regulations should be aware that use of this compound is prohibited in sport regardless of the circumstances of access.
For official information on unapproved peptide products in Australia, the TGA's published guidance is the authoritative source.
The following official sources provide authoritative information on CJC-1295 and unapproved therapeutic goods in Australia:
This article is for general educational purposes only. Nothing on this page constitutes medical advice or a recommendation to use, seek, obtain or purchase CJC-1295 or any other unapproved therapeutic product. Always consult a qualified, AHPRA-registered medical practitioner before making decisions about your health. For the TGA's current position on unapproved peptide products, visit www.tga.gov.au.